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CHAPTER 1 
Background and Aim of the Work 
 
Diabetes Mellitus (DM) comprises a group of common metabolic 
disorders that share the phenotype of hyperglycaemia. Several distinct 
types of DM exist and are caused by a complex interaction of genetic and 
environmental factors, and life-style choices. Depending on the etiology 
of the DM, factors contributing to hyperglycaemia may include reduced 
insulin secretion, decreased glucose utilization and increased glucose 
production. The metabolic dysregulation associated with DM causes 
secondary pathophysiologic changes in multiple organ systems that 
impose a tremendous burden on the individual with diabetes and on the 
health care system. In the United States, DM is the leading cause of end-
stage renal disease (ESRD), nontraumatic lower extremity amputations, 
and adult blindness. With an increasing incidence worldwide, DM will be 
a leading cause of morbidity and mortality for the foreseeable future [1]. 
DM is classified on the basis of the pathogenic process that leads to 
hyperglycaemia. The two broad categories of DM are designed type 1 and 
type 2. Type 1A DM results from autoimmune beta cell destruction, 
which leads to insulin deficiency. Individuals with type 1B DM lack 
immunologic markers indicative of an autoimmune destructive process of 
the beta cells. However, they develop insulin deficiency and are ketosis 
prone. Relatively few patients with type 1 DM are in the type 1B 
idiopathic category. Type 2 DM is an heterogeneous group of disorders 
characterized by variable degrees of insulin resistance, impaired insulin 
secretion and increased glucose production. Distinct genetic and 
metabolic defects in insulin action and/or secretion give rise to the 
common phenotype of hyperglycaemia in type 2 DM [1]. 
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Type 1 Diabetes Mellitus 
Type 1A DM develops as a result of the synergistic effects of genetic, 
environmental, and immunologic factors that ultimately destroy the 
pancreatic beta cells. The temporal development of type 1A DM is shown 
schematically as a function of beta cell mass. Individuals with a genetic 
susceptibility have normal beta cell mass at birth but begin to lose beta 
cells secondary to autoimmune destruction that occurs over months to 
years. This autoimmune process is thought to be triggered by an 
infectious or environmental stimulus and to be sustained by a beta cell-
specific molecule. In the majority of individuals, immunologic markers 
appear after the triggering event but before diabetes becomes clinically 
overt. Beta cell mass then begins to decline, and insulin secretion 
becomes progressively impaired, although normal glucose tolerance is 
maintained. The rate of decline in beta cell mass widely varies among 
individuals, with some patients progressing rapidly to clinical diabetes 
and others evolving more slowly. Features of diabetes do not become 
evident until a majority of beta cells are destroyed (80%) and the 
individual becomes completely insulin deficient [1]. 
Genetic susceptibility to type 1A DM involves multiple genes. The 
concordance of type 1A DM in identical twins ranges between 30 and 
70%, indicating that additional modifying factors must be involved in 
determining whether diabetes develops. The major susceptibility gene for 
type 1A DM is located in the HLA region on chromosome 6. 
Polymorphisms in the HLA complex account for 40 to 50% of the genetic 
risk of developing type 1A DM. Most individuals with type 1A DM have 
the HLA DR3 and/or DR4 haplotype. Refinements in genotyping of HLA 
loci have shown that the haplotypes DQA1*0301, DQB1*0302, 
DQA1*0501, and DQB1*0201 are most strongly associated with type 1A 
DM. The risk of developing type 1A DM is increasing tenfold in relatives 
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of individuals with the disease. Nevertheless, most individuals with 
predisposing haplotypes do not develop diabetes. In addition, most 
individuals with type 1A DM do not have a first-degree relative with the 
disorder [1]. 
 
Type 2 Diabetes Mellitus 
Type 2 DM is characterized by three pathophysiologic abnormalities: 
impaired insulin secretion, peripheral insulin resistance, and excessive 
hepatic glucose production. Obesity, particularly visceral or central (as 
evidenced by the hip-waist ratio), is very common in type 2 DM. In the 
early stages of the disorder, glucose tolerance remains normal, instead of 
insulin resistance, because the pancreatic beta cells compensate by 
increasing insulin output. As insulin resistance and compensatory 
hyperinsulinemia progress, the pancreatic islets in certain individuals are 
unable to sustain the hyperinsulinemic state. Later on, impaired glucose 
tolerance, characterized by elevations in postprandial glucose, develops. 
A further decline in insulin secretion and an increase in hepatic glucose 
production lead to overt diabetes with fasting hyperglycaemia. 
Ultimately, beta cell failure may ensue [1]. 
 
Metabolic abnormalities 
Insulin resistance – The decreased ability of insulin to effectively act on 
peripheral target tissues (especially muscle and liver) is a prominent 
feature of type 2 DM and results from a combination of genetic 
susceptibility and obesity. Insulin resistance is relative, however, since 
the supernormal levels of circulating insulin will normalize the plasma 
glucose. Insulin dose-response curves exhibit a rightward shift, indicating 
reduced sensitivity, and a reduced maximal response, indicating an 
overall decrease in maximum glucose utilization (30 to 60% lower than 
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healthy individuals). Insulin resistance impairs glucose utilization by 
insulin sensitive tissues and increases hepatic glucose output; both effects 
contribute to the hyperglycaemia. Increased hepatic glucose output 
predominantly accounts for increased fasting plasma glucose levels, 
whereas decreased peripheral glucose utilization results in postprandial 
hyperglycaemia. The precise molecular mechanism of insulin resistance 
in type 2 DM has not been elucidated. Insulin receptor levels and tyrosine 
kinase activity in skeletal muscle are reduced, but these alterations are 
most likely secondary to hyperinsulinemia rather than a primary defect. 
Therefore, postreceptorial defects are believed to play the predominant 
role in insulin resistance.  
Another emerging theory proposes that elevated levels of free fatty acids 
(FFA), a common feature of obesity, may contribute to the pathogenesis 
of type 2 DM. FFA can impair glucose utilization in skeletal muscle, 
promote glucose production by the liver, and impair beta cell function 
[1]. 
Impaired insulin secretion – Insulin secretion and sensitivity are 
interrelated. In type 2 DM, insulin secretion initially increases in response 
to insulin resistance to maintain normal glucose tolerance. At the 
beginning, the insulin secretory defect is mild and selectively involves 
glucose-stimulated insulin secretion. The response to other non-glucose 
secretagogues, such as arginine, is preserved. Eventually, the insulin 
secretory defect progresses to a state of grossly inadequate insulin 
secretion. The reason(s) for the decline in insulin secretory capacity in 
type 2 DM is unclear. The metabolic environment of diabetes may also 
negatively impact islet function. For example, chronic hyperglycaemia 
paradoxically impairs islet function (“glucose toxicity”) and leads to a 
worsening of hyperglycaemia. Improvement in glycaemic control is often 
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associated with improved islet function. In addition, elevation of FFA 
levels (“lipotoxicity”) and dietary fat may also worsen islet function. 
Increased hepatic glucose production – In type 2 DM, insulin resistance 
in the liver, reflects the failure of hyperinsulinemia to suppress 
gluconeogenesis, which results in fasting hyperglycaemia and decreased 
glycogen storage by the liver in the postprandial state. Increased hepatic 
glucose production occurs early in the course of diabetes, though likely 
after the onset of insulin secretory abnormalities and insulin resistance in 
skeletal muscle. 
 
Genetic considerations 
As mentioned above, insulin resistance and impaired beta cell function 
are the prominent features of type 2 DM, and they are contributed by both 
genetic and environmental factors. These factors might affect either the 
process of insulin signal transmission across the plasma membrane and/or 
the biochemical pathways allowing glucose uptake and metabolism by 
the cells, or might affect the pathways regulating beta cell function, 
including those for beta cell compensation. While several environmental 
factors have been identified, discovery and characterization of the genes 
involved in type 2 DM has been an arduous task and has proceeded 
slowly. In the past ten years, indeed, geneticists have devoted a large 
amount of efforts to find type 2 DM genes. These efforts have included 
many candidate-gene studies, extensive efforts to fine map linkage 
signals, and an international linkage consortium that was perhaps the best 
example of a multi-centre collaboration in common-disease genetics 
(Genome Wide Association Studies – GWAS). Among these efforts, only 
the candidate-gene studies produced unequivocal evidence for common 
variants involved in type 2 DM. These are the E23K variant in the 
potassium inwardly-rectifying channel, subfamily J, member 11 
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(KCNJ11) gene [2], the P12A variant in the peroxisome proliferator-
activated receptor γ (PPARG) gene [3], and common variations in the 
hepatic transcription factor 2 (TCF2)  [4] and the Wolfram syndrome 1 
(WSF1) 10 genes [5]. All of these genes encodes proteins that have 
strong biological links to diabetes. Rare, severe mutations in these four 
genes cause monogenic forms of diabetes, and two of them are targets of 
currently used anti-diabetic drugs: KCNJ11 encodes a component of a 
potassium channel with a key role in beta cell physiology and is targeted 
by the sulphonylurea class of drugs; PPARG encodes a nuclear receptor 
involved in adipocyte differentiation and is targeted by the 
thiazolidinedione class of drugs (Fig.1). 
A common amino-acid polymorphism (Pro12Ala) in peroxisome 
proliferator-activated receptor g (PPAR-g) has been associated with type 
2 DM. People homozygous for the Pro12 allele are more insulin resistant 
than those having one Ala12 allele and have a 1.25-fold increased risk of 
developing diabetes. Moreover, there is also evidence for interaction 
between this polymorphism and fatty acids, thereby linking this locus 
with diet [3]. 
In 2006, by far the most spectacular recent development in the genetics of 
type 2 DM has been the identification of TCF7L2 (encoding transcription 
factor-7 like 2) as the most important type 2 DM susceptibility gene to 
date [6]. The estimate of effect size (an odds ratio for type 2 DM of 1.4-
fold per allele) was identified in an intronic SNP with uncertain 
functional credentials (rs7903146). TCF7L2 variation is strongly 
associated with rates of progression from impaired glucose tolerance to 
diabetes (with a hazard ratio of 1.55 between homozygote groups). 
TCF7L2 is widely expressed and involved in the Wnt signalling cascade. 
Most studies suggest that the predominant intermediate phenotype 
associated with TCF7L2 variation is impaired insulin secretion, 
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consistent with the replicated observation that the TCF7L2 association is 
greater among lean than obese type 2 DM subjects. 
TCF7L2 result was encouraging for two reasons. Firstly, the study 
analyzed more than 200 markers across a region of linkage on 
chromosome 10q, but the variants that were found to alter risk did not 
explain the linkage signal, suggesting that a non-candidate gene or 
region-based association effort (such as GWAS) could work. Secondly, 
TCF7L2 was a completely unexpected gene, showing that a genome-wide 
approach could uncover previously unexpected disease pathways. 
   
 
Figure 1 – Effect sizes of the 11 common variants confirmed to be involved in 
type 2 diabetes risk. 
The x axis shows the year when published evidences reached the levels of statistical 
confidence that are now accepted as necessary for genetic association studies. 
CDKAL1, CDK5 regulatory subunit associated protein-1 like 1; CDKN2, cyclin-
dependent kinase inhibitor 2A; FTO, fat mass and obesity-associated; HHEX, 
haematopoietically expressed homeobox; IDE, insulin-degrading enzyme; IGF2BP2, 
insulin-like growth factor 2 mRNA-binding protein 2; KCNJ11, potassium inwardly-
rectifying channel, subfamily J, member 11; PPARG, peroxisome proliferator-
activated receptor-g gene; SLC30A8, solute carrier family 30 (zinc transporter), 
member 8; TCF2, transcription factor 2, hepatic; TCF7L2, transcription factor 7-like 2 
(T-cell specific, HMg-box); WSF1 Wolfram syndrome 1.  
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PED/PEA-15 (Phosphoprotein Enriched in Diabetes / 
Phosphoprotein Enriched in Astrocytes of 15 KDa) 
 
PED/PEA-15 identification 
Some years ago, during a differential display-based study carried out in 
our lab to identify genes whose expression was altered in type 2 DM, the 
protein kinase C (PKC) substrate PEA-15 (Phosphoprotein Enriched in 
Astrocytes 15) was found overexpressed in fibroblast, skeletal muscle and 
adipose tissue from type 2 diabetics compared to healthy subjects. Given 
its overexpression in type 2 DM, the PEA-15 gene was re-named PED 
which stands for Phosphoprotein Enriched in Diabetes [7].  
Much more recently, the PED overexpression finding has been replicated 
in a different population of type 2 diabetics and in a population of healthy 
subjects at high risk of developing diabetes, such as the first degree 
relatives of type 2 diabetics (FDR). Furthermore, in these same subjects, 
PED expression levels inversely correlate with insulin sensitivity in 
skeletal muscle [8]. These last evidences suggest that PED/PEA-15 may 
contribute to the early appearance of insulin resistance in healthy 
individuals at high risk of diabetes. 
 
PED/PEA-15 
PED/PEA-15 was originally identified as a major astrocytes 
phosphoprotein and it was found to be widely expressed in different 
tissues and highly conserved among mammals. PED/PEA-15 is a 15KDa 
cytosolic protein whose gene maps on chromosome 1q21-22 [7]. It is a 
highly regulated protein with two major phosphorylation sites on Ser104 
and Ser116. Indeed, PED/PEA-15 is phosphorylated at Ser104 by the 
protein kinase C (PKC) and at Ser116 by the calcium-calmodulin kinase 
II (CAMKII) and by Akt/PKB [9; 10]. Moreover, it presents at the N-
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terminus the protein-protein interaction domain DED (Death Effector 
Domain) and a NES (Nuclear Export Signal), that localizes the protein 
prevalently into the cytosol (Fig.2).  
   
 
Figure 2 – Schematic representation of the PED/PEA-15 protein 
 
Several studies in cultured cells and in rodent tissues have revealed that 
PED/PEA-15 is a multifunctional protein. I) It regulates multiple cellular 
function by binding to distinct components of major intracellular 
transduction pathways [11-13]. These include PLD1, ERK1/2, Akt/PKB 
and RSK2. II) It has been shown to exert antiapoptotic action by distinct 
mechanisms. Firstly, PED/PEA-15 inhibits the formation of the death-
inducing signalling complex (DISC) and caspase 3 activation by different 
apoptotic cytokines including FAS ligand, tumour necrosis factor alpha, 
and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) 
[14; 15]. At least in part, this action is accomplished through the DED of 
PED/PEA-15 upon PED/PEA-15 recruitment to the DISC. Secondly, 
PED/PEA-15 inhibits the induction of different stress-activated protein 
kinases (SAPKs) triggered by growth factor deprivation, hydrogen 
peroxide and anisomycin [16]. This action of PED/PEA-15 is exerted by 
the blocking of an upstream event in the SAPK activation cascade and 
requires the interaction of PED/PEA-15 with ERK1/2. Thirdly, 
PED/PEA-15 modulates apoptosis upon UVC exposure in a dose-
dependent fashion. Indeed, at least in part, apoptosis following 
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Omi/HtrA2 mitochondrial release is mediated by reduction in PED/PEA-
15 cellular levels [17]. Thus, the ability of Omi/HtrA2 to relieve XIAP 
inhibition on caspases is modulated by the relative levels of Omi/HtrA2 
and PED/PEA-15.  
III) It plays an important role in tumour development and sensitivity to 
antineoplastic agents [18]. Indeed, the expression levels of PED/PEA-15 
control caspase 3 function and epidermal cell apoptosis in vivo and 
determine susceptibility to skin tumour development. IV) PED/PEA-15 
also binds to and increases the stability of the phospholipase D1, 
enhancing its activity and controlling important mechanisms in cell 
metabolism [11]. In cultured muscle and adipose cells and in tissues from 
transgenic mice, high levels of PED/PEA-15 impair insulin-stimulated 
GLUT4 translocation to the plasma membrane and glucose transport 
suggesting that PED/PEA-15 overexpression may contribute to insulin 
resistance in type 2 DM [19; 20]. Moreover, other studies have 
demonstrated that PED/PEA-15-induced resistance to insulin action on 
glucose disposal is accompanied by PLD-dependent activation of the 
classical protein kinase C isoform PKCalpha. In turn, the induction of 
PKCalpha by PED/PEA-15 prevents subsequent activation of the atypical 
PKCzeta by insulin [19]. Thus, in muscle and adipose cells, PED/PEA-15 
generates resistance to insulin action on glucose disposal by impairing 
normal regulation of PKCzeta (Fig.3). 
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Figure 3 – Proposed mechanism of PED/PEA-15 action on insulin-stimulated 
glucose transport. 
 
Transgenic mice ubiquitously overexpressing ped/pea-15 (Tg-PED) at 
levels comparable to those found in many type 2 diabetics, exhibited 
mildly elevated random-fed blood glucose levels and decreased glucose 
tolerance. These mice develop diabetes only when they are fed with a 
60% fat diet [20], indicating that ped/pea-15 overexpression alone is able 
to generate a metabolic background prone to diabetes development. Much 
more recently a beta-cell specific ped/pea-15 transgenic animal has been 
generated to further elucidate the role of ped/pea-15 in the glucose-
induced insulin secretion. It has been shown that ped/pea-15 
overexpression in the beta-cell is able to impair glucose-induced insulin 
secretion by restraining potassium channel expression [21]. 
 
REGULATION OF GENE EXPRESSION BY THE 
SUPERFAMILY OF HORMONE NUCLEAR RECEPTORS 
 
The nuclear receptor superfamily includes receptors for hormones such as 
steroids, thyroid hormone, retinoic acid and vitamin D, as well as a large 
number of homologous proteins with no ligand identified, termed the 
orphan receptors [22]. Many non-steroid hormone receptors, including 
 11
the thyroid hormone receptor (TR) and retinoic acid receptor (RAR), 
function as heterodimers with the retinoid X receptor (RXR). The 
receptors bind to specific DNA sequences in the promoter regions of 
target genes and activate transcription in the presence of cognate ligand. 
In addition, receptors such as TR and RAR repress transcription in the 
absence of ligand. It is important to point out that this refers to repression 
of basal transcription, rather than inhibition of activated transcription, as 
is associated with hormone-induced negative regulation. 
 
Biological/Pathological significance of repression by nuclear receptors 
The ability of nuclear receptors to bind and repress target genes in the 
absence of ligand serves to amplify the activating effect of hormonal 
signals. There is abundant and long-standing evidence for a biological 
role for the hormonal activation of nuclear receptors, but only recently 
has the importance of basal repression been appreciated. Initial clues 
came from the study of acute promyelocytic leukemia (APL). APL is 
associated with rearrangements of the gene encoding RAR-α (RARA), 
which produce abnormal fusion proteins that block myeloid 
differentiation. This differentiation block correlates with the ability of the 
fusion protein to repress transcription. Treatment with retinoic acid, 
which abolishes the RAR-mediated repression, relieves this block and 
results in complete remission of the disease in most patients, including 
those with the most common rearrangement involving the promyelocytic 
leukaemia gene (PML). However, patients in whom the RARA gene is 
fused to the promyelocytic leukemia zinc finger (PLZF) gene (ZNF145) 
are resistant to retinoic acid [23]. This correlates with an independent, 
retinoic acid resistant-repression function of PLZF [24-27]. The 
importance of the repression complex in leukemia is not restricted to 
APL. Acute myeloid leukemia (AML) caused by fusion of the AML 
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protein to the ETO (eight twenty one or MTG8) protein has also been 
linked to nuclear receptor repression mechanisms [28-30]. In addition, an 
oncogenic form of the TR, v-ErbA, contributes to avian erythroblastosis 
virus-induced leukemic transformation by repressing transcription of 
target genes [31]. Repression is also implicated in the syndrome of 
thyroid hormone (TH) resistance, which is caused by mutations in the 
ligand-binding domain (LBD) of the TR. The severity of the resistance 
correlates with the repression function of the mutant TR [32; 33]. 
Recent evidence also suggests a role for repression in normal thyroid 
physiology. The phenotype of mice lacking all known TRs is less 
severely altered than that of mice lacking TH [34]. A major difference 
between the two models is the presence of unoccupied receptor in the 
case of TH deficiency. This implies a role for the unliganded receptor in 
normal biology; for example, basal repression of target genes. 
 
The Hepatocyte Nuclear Factor-4alpha and the Chicken Ovalbumin 
Upstream Promoter-Transcription Factor II 
Hepatocyte Nuclear Factor-4alpha (HNF-4alpha) and the Chicken 
Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII) are 
two members of the steroid/thyroid superfamily of transcription factors 
involved in the control of glucose homeostasis [35-37]. Studies in mice in 
which the early lethal phenotype is circumvented have revealed that 
HNF-4alpha is essential for hepatocyte differentiation both at the 
morphological and the functional levels [38] and for accumulation of 
hepatic glycogen stores and generation of normal hepatic epithelium [39]. 
Point mutations in HNF-4alpha impair liver and pancreatic regulation of 
glucose homeostasis and cause Maturity Onset Diabetes of the Young 
type 1 (MODY1). More recently, genetic and biochemical evidence has 
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been generated indicating that HNF-4alpha may also have a role in the 
development of more common forms of type 2 diabetes [40-42].  
Most of the promoter elements interacting with HNF-4alpha can also 
recognize the Chicken Ovalbumin Upstream Promoter Transcription 
Factors (COUP-TFs) [43-45] one of the most extensively studied orphan 
receptors. COUP-TFs regulate a number of biological processes including 
embryonic development [46] and neural cell fate determination [47]. 
COUP-TFs may also affect glucose homeostasis. Indeed, in vitro studies 
indicate that COUP-TFII, also termed Arp-1, regulates several genes 
involved in glucose and lipid metabolism including insulin gene 
expression in pancreatic beta-cells [48; 49]. Functionally, COUP-TFII has 
been identified as a transcriptional repressor of genes activated by HNF-
4alpha. However, evidence is also present in the literature indicating that, 
at least in certain circumstances, COUP-TFII activates gene expression 
[50; 51]. The specific function of COUP-TFII likely depends upon the 
repertoire of coregulatory proteins interacting with COUP-TFII and HNF-
4alpha in each specific context [52-60]. 
 
Hormone nuclear receptors and chromatin remodelling 
Hormone nuclear receptors are ligand-activated transcription factors that 
regulate a vast array of biological processes by modulating expression of 
specific target genes [61; 62]. Their ability to modulate transcription 
depends on the recruitment of cofactors that remodel chromatin and the 
assembly of basal transcription machinery [63; 64]. 
Chromatin is the state in which DNA is packaged within the cell. The 
nucleosome is the fundamental unit of chromatin and it composed of an 
octamer of the four core histones (H3, H4, H2A, H2B) around which 147 
base pairs of DNA are wrapped. The core histones are predominantly 
globular except for their N-terminal “tails”, which are unstructured. A 
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striking feature of histones, and particularly of their tails, is the large 
number and type of modified residues they possess (Fig.4). 
 
Figure 4 – Chromatin organization of the tail of histone H3 - a, General chromatin 
organization. Like other histone 'tails', the N terminus of H3 (red) represents a highly 
conserved domain that is likely to be exposed or extend outwards from the chromatin 
fibre. A number of distinct post-translational modifications are known to occur at the 
N terminus of H3 including acetylation (green flag), phosphorylation (grey circle) and 
methylation (yellow hexagon). Other modifications are known and may also occur in 
the globular domain. b, The N terminus of human H3 is shown in single-letter amino-
acid code. For comparison, the N termini of human CENP-A, a centromere-specific 
H3 variant, and human H4, the nucleosomal partner to H3, are shown. Note the 
regular spacing of acetylatable lysines (red), and potential phosphorylation (blue) and 
methylation (purple) sites. The asterisk indicates the lysine residue in H3 that is 
known to be targeted for acetylation as well as for methylation; lysine 9 in CENP-A 
(bold) may also be chemically modified. The above depictions of chromatin structure 
and H3 are schematic; no attempt has been made to accurately portray these 
structures. 
 
Histone modifications in chromatin, particularly histone methylation, 
play key roles in gene expression and are emerging as a visible new layer 
of gene expression regulation [65-67]. Depending upon the timing and 
chromosomal location, histone methylation can not only undergo 
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dynamic changes during gene transcription and cell division, but also 
remain semi-stable, well maintained, and somatically inheritable. Along 
with DNA methylation, histone methylation can contribute to epigenetic 
heritable changes in gene function that do not involve a local change in 
DNA sequence. It has been shown that changes in histone methylation 
follow specific patterns and encode informations during cell cycle 
changes and development [68]. Therefore, aberrant alterations in histone 
lysine methylation patterns that change chromatin structure could lead to 
dysregulated gene transcription and disease progression [69]. Together 
with histone methylation, the acetylation status of histone proteins alters 
gene transcription. Removal of acetyl groups from lysine residues results 
in histone methylation, compaction of chromatin and, hence, repression 
of gene transcription [70]. As such, transcriptionally active euchromatin 
is tipically hyperacetylated and hypomethylated, compared with inactive 
heterochromatin which tends to be hypoacetylated and hypermethylated 
[71]. Elucidating the biological and functional relevance of these post-
translational histone modifications is crucial to our understanding of the 
role of chromatin in gene expression and disease. 
Chromatin remodelling is achieved by enzymes that catalyses post 
translational modifications of histones and the shuttling of nucleosomes 
by ATP-dependent mechanisms. The histone modifications, which 
include acetylation, methylation, phosphorylation, ubiquitylation, 
sumoylation, deimination, ADP ribosylation and proline isomerization, 
lead alterations in the accessibility of chromatin and allow for regulated 
transcription of genes [72]. These modifications, which may take place 
sequencially or in combination are proposed to constitute a “histone 
code” [73-75] that dictates the transcription state of genes (Fig.5).  
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Figure 5 – The “Histone Code” hypothesis - Histone modifications occur at selected 
residues and some of the patterns shown have been closely linked to a biological 
event (for example, acetylation and transcription). Emerging evidence suggests that 
distinct H3 (red) and H4 (black) tail modifications act sequentially or in combination 
to regulate unique biological outcomes. How this hierarchy of multiple modifications 
extends (depicted as 'higher-order combinations') or how distinct combinatorial sets 
are established or maintained in localized regions of the chromatin fibre is not known. 
Relevant proteins or protein domains that are known to interact or associate with 
distinct modifications are indicated. The CENP-A tail domain (blue) might also be 
subjected to mitosis-related marks such as phosphorylation; the yellow bracket depicts 
a motif in which serines and threonines alternate with proline residues. 
 
In addition to histone modifications, DNA methylation is a key epigenetic 
mechanism for gene silencing [76]. Methylation at cytosine residues of 
the dinucleotide sequence CpG is essential for animal development [77] 
and irregular methylation patterns lead to cancer [78]. 
The diverse biological processes regulated by nuclear receptors are 
attributed to differential recruitment of coactivators and corepressors that 
function as scaffolds for the recruitment of chromatin remodelling 
enzymes. In the absence of ligand, certain nuclear receptors recruit 
corepressors such as the Silencing Mediator of Retinoic acid and Thyroid 
hormone receptors (SMRT) and the Nuclear receptor corepressor (N-Cor) 
that bind repressive enzymes such as histone deacetylase enzymes 
 17
(HDAC) [79] or the histone methyl transferase (HMT) SUV39H1, which 
specifically methylates histone H3 at lysine 9 (H3K9) [80]. On the other 
hand, ligand bound nuclear receptors can also bind corepressors such 
RIP140 [81] and L-Cor [82] to actively repress gene expression (Fig.6). 
 
 
Fig. 6 – Nuclear Receptor Co-repressors (A) Transcriptional repression by nuclear 
receptors is regulated by recruitment of the co-repressors N-CoR and/or SMRT. 
(B) The domains of N-CoR/SMRT. Repression domains (RI, RII, RIII) and SANT 
domains (A and B) are indicated, as are interaction domains for HDACs, nuclear 
receptors (I and II) and other transcription factors. (C) N-CoR–SMRT compexes. 
Biochemical purification techniques have revealed several different complexes 
recruited by N-CoR and/or SMRT [83-87] 
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AIM OF THE STUDY 
 
PED/PEA-15 overexpression is a common feature of both type 2 diabetic 
individuals and healthy subjects at high risk of developing the disease, 
such as healthy first degree relatives of type 2 diabetic subjects.  
Since no alteration in the DNA sequence of the PED/PEA-15 gene has 
been found up to now which could account for the altered expression, the 
general aim of my research has been to discover new mechanisms 
involved in the regulation of its expression and potentially deregulated in 
diabetic conditions. 
I have firstly cloned and characterized the promoter region of the human 
PED/PEA-15 gene and obtained evidence that HNF-4alpha binds an HNF 
Response Element (HRE) on the promoter of the gene and represses its 
transcription.   
Once established the role of the HNF-4alpha as an inhibitor of PED/PEA-
15 expression, at least in the liver, the aim of my further studies has been 
to clarify the molecular mechanisms by which HNF-4alpha exerts its 
action once bound to the HRE on the promoter of the PED/PEA-15 gene.    
To this aim, I have investigated: 1) whether HNF-4alpha acts “passively” 
on PED/PEA-15 expression by competing with an activator for the 
binding to the promoter of the gene; 2) and whether, given its belonging 
to the superfamily of the hormone nuclear receptors, HNF-4alpha is able 
to recruit co-repressor complexes on PED/PEA-15 promoter and inhibit 
its expression by modifying the accessibility of the core-promoter region 
to the basal transcriptional machinery. 
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Chapter 2 
Materials  and  Methods 
 
Materials. Media, sera, and antibiotics for cell culture and the 
Lipofectamine reagent were purchased from Invitrogen Ltd. (Paisley, 
United Kingdom). Goat polyclonal HNF-4alpha, SMRTe and Acetyl-
Histone H3 K9/K14 (AcH3)  and rabbit polyclonal COUP-TFII 
antibodies were from Santa Cruz Biotechnology (Santa Cruz, Calif.). 
Rabbit monoclonal Di-methyl-H3-lysine 4 (H3K4) and mouse 
monoclonal Di-methyl-H3 lysine 9 (H3K9) were from AbCam 
(Cambridge – UK). PED/PEA-15 antibody has been previously described 
[7; 10]. The mouse monoclonal HA antibody was from Boehringer 
Mannheim. The Protein A- and G-Sepharose beads were from Pierce 
(Rockford, IL). The pCDNA3/HNF-4alpha expression vector, which 
contains the HNF-4alpha coding region, was a generous gift from Dr. 
Graeme Bell (Department of Medicine, University of Chicago, Chicago, 
Illinois). The pCMV6-XL5COUP-TFII expression plasmid and the 
pCMV6-XL5 vector were from OriGene Technologies, Inc. (Rockville, 
MD). Radiochemicals, Western blot and ECL reagents were purchased 
from Amersham Pharmacia Biotech. All other reagents were from Sigma 
(St. Louis, MO).  
 
Plasmid constructs. A 2.0 Kb KpnI-XhoI genomic fragment containing 
the 5’-flanking region of the human PED/PEA-15 gene was amplified 
(PCR) and subcloned between the corresponding restriction sites of the 
luciferase expression vector pGL3 Basic (Promega, Madison, WI). The 
resulting plasmid, termed pPED2000, was used as a template for PCR 
generation of progressively deleted fragments of the PED/PEA-15 5’-
flanking region. These were also subcloned in the luciferase cloning 
vector. To minimize the possibility of introducing errors during the PCR, 
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the Expand Long Template PCR System (Roche Mannheim) was used 
and DNA was amplified according to the manufacturer’s instructions. 
The identity and orientation of the PCR fragments were then assessed by 
restriction enzyme analysis and sequencing.  
The HNF-4alpha binding site on PED/PEA-15 promoter 
(TCATCCAAAGGTCA) was mutagenized by PCR to 
TCATCCCCCGGTCA. Two mutated inner primers (pPED477mutFor   
CGTGGTCATCCCCCGGTCAAAAG and pPED477mutRev 
CTTTTGACCGGGGGATGACCAGG) and two outer primers (Ped477 
KpnI and Ped (XhoI) antisense – see table1) were used. Two mutated 
products were amplified using the pPED477 construct as a template and 
the Expand Long Template PCR System (Roche) to minimize the 
possibility of introducing errors during the PCR. In the first reaction the 
mutated inner sense primer was used together with the Ped (XhoI) 
antisense, while the Ped477 KpnI primer was used in the second reaction 
together with the mutated inner antisense. The mutant HRE was then 
reconstituted with the Expand Long Template PCR System (Roche) using 
the outer primers.  
The mutant fragment (477mut) obtained was then inserted into the pGL3 
Basic Vector and completely sequenced. 
All siRNAs were chemically synthesized by Ambion (Austin, TX) as 
oligonucleotide duplexes. siRNA target sequences for SMRT were 
directed at regions common to both SMRTα and SMRTβ (panSMRT, 5’-
GGGTATCATCACCG CTGTG-3’ [88]. As nonspecific siRNA controls, 
an siRNA sequence targeting luciferase (5’-CGTACGCGGAATACTTC 
GA-3’) was used. 
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Cell culture, transfections, RT-PCR, and Western Blot assay.  Hela, and 
HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, Penicillin (200 IU/ml), 
Streptomycin (100 μg/ml), and 2% L-glutamine in a humidified CO2 
incubator. Stable expression of the HNF-4alpha sh-RNA clone in HepG2 
cells and wild type HNF-4alpha cDNA in Hela cells was achieved as 
reported by Condorelli et al (16). Transient transfection of plasmid DNAs 
in Hela,  and HepG2 cells were carried out by the calcium phosphate 
coprecipitation method [89]. Briefly, the cells were plated in 60-mm 
dishes prior to transfection at a confluence of 1 x 105 cells/dish. 3 μg of 
the indicated PED/PEA-15 promoter-luciferase construct and 1 μg of the 
pRSVβ-gal vector (to correct for the variable transfection efficiencies) 
were then added.  
To examine the effect of HNF-4alpha and COUP-TFII on PED/PEA-15 
promoter, Hela and HepG2 cells were cotransfected with 2 μg of 
PED/PEA-15 promoter-luciferase together with different amounts of 
HNF-4alpha and COUP-TFII expression vectors. Total DNA content (up 
to 4 μg/plate) was normalized to the empty vector devoid of HNF-4alpha 
and COUP-TFII coding sequence. 48 h after transfection, the cells were 
harvested and lysed as described previously [60]. Luciferase activity was 
measured by a commercial luciferase assay kit (Promega). Values were 
normalized for β-galactosidase. Statistical significance was evaluated by 
t-test analysis. 
Total RNAs were prepared by extraction with the RNeasy Kit (Qiagen 
Sciences) according to the manufacturer’s instructions. For Real-Time 
RT-PCR analysis, 1 μg RNA was reverse-transcribed using the 
Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA). 
Reactions were performed using Platinum SYBR Green qPCR Super-
UDG in a iCycler IQ multicolor Real Time PCR Detection System 
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(Biorad, Hercules, CA). All reactions were performed in triplicate, and β-
actin was used as internal standard. 
For Western blot and Co-immunoprecipitation analysis, cells were 
solubilized in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10 
mM EDTA, 10 mM Na2P2O7, 2 mM Na3VO4, 100 mM NaF, 10% 
glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride, 10 
µg/ml aprotinin) for 2 h at 4°C. Cell lysates were clarified by 
centrifugation at 5,000 x g for 20 min, separated by SDS-PAGE (or firstly 
immunoprecipitated), and transferred into 0.45-µm Immobilon-P 
membranes (Millipore, Bedford, MA). Upon incubation with primary and 
secondary antibodies, immmunoreactive bands were detected by ECL 
according to the manufacturer's instructions. 
shRNA-mediated knockdown of HNF-4alpha To interfere with 
endogenous HNF-4alpha expression in HepG2 cells, we use short-hairpin 
RNAs with the following sequences: clone a (Cl.a) 
CCGGCCATCACCAAGCAGGAAGTTACTCGAGTAA 
CTTCCTGCTTGGTGATGGTTTTT; clone b (Cl.b) 
CCGGACCACCCTGGAATTT 
GAGAATCTCGAGATTCTCAAATTCCAGGGTGGTTTTTT. The 
cells were transfected with 1 μg of each clones using the Lipofectamine 
reagent according to manufacturer’s recommendations and analyzed 48 h 
after transfection.  
 
5-aza-2’-deoxycytidine and trichostatin A treatment HepG2 cells were 
seeded in 10 cm dishes at a density of 1 X 106 cells 1 day before the drug 
treatment. The cells were treated with 10 mM 5-aza-2’-deoxycytidine (5-
aza-dC; Sigma, St Louis, MO) for 24 h then harvested.  
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Another culture of cells was treated with 330 nM trichostatin A (TSA; 
Sigma) for 1 day. To test the combined effect of 5-aza-dC and TSA, cells 
were treated with 10 mM 5-aza-dC and 330 nM TSA for 24h.  
Total RNA and chromatin were prepared and tested for restoration of 
PED/PEA-15 and HNF-4alpha expression by real-time RT–PCR and 
HNF-4alpha occupancy and PED/PEA-15 promoter modifications by 
ChIP assays.  
 
FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) assay. 
The cross-linking solution, containing 1% formaldehyde, was added 
directly to cell culture media. The fixation proceeded for 10 min and was 
stopped by the addition of glycine to a final concentration of 125 mM. 
cells were rinsed twice with cold PBS plus 1 mM PMSF, and then (Hela 
and HepG2) scraped. Cells were collected by centrifugation at 800 X g 
for 5 min at 4°C. Cells were swelled in cold cell lysis buffer containing 5 
mM piperazine-N,N’-bis (2ethanesulfonic acid) (pH 8.0), 85 mM KCl, 
0.5% Nonidet P-40, 1 mM PMSF and inhibitors cocktail (Sigma) and 
incubated on ice for 10 min. Nuclei were precipitated by 
microcentrifugation at 2000 X g for 5 min at 4°C, resuspended in nuclear 
lysis buffer containing 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.8% 
sodium dodecyl sulphate (SDS), 1 mM PMSF and inhibitors cocktail 
(Sigma), and then incubated on ice for 10 min. Samples were broken by 
sonication into chromatin fragments of an average length of 500/1000 bp 
and then microcentrifuged at 16,000 X g for 10 min at 4°C. Protein-free 
DNA was then extracted with Phenol-Chloroform-Isoamyl alcohol 
(25:24:1) and  precipitated. The pellets were resuspended in 30 μl of TE 
and analyzed by PCR using specific primers for the analyzed regions. The 
input sample (obtained by a step of reversal cross-link, deproteinization 
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and extraction as described below) was resuspended in 30 μl of TE and 
diluted 1:10 before PCR.   
 
Chromatin Immuno-precipitation (ChIP) and ReChIP assay. The cross-
linking solution, containing 1% formaldehyde, was added directly to cell 
culture media. The fixation proceeded for 10 min and was stopped by the 
addition of glycine to a final concentration of 125 mM. Primary human 
hepatocytes (Lonza Walkersville), Hela and HepG2 cells were rinsed 
twice with cold PBS plus 1 mM PMSF, and then (Hela and HepG2) 
scraped. Cells were collected by centrifugation at 800 X g for 5 min at 
4°C. Cells were swelled in cold cell lysis buffer containing 5 mM 
piperazine-N,N’-bis (2ethanesulfonic acid) (pH 8.0), 85 mM KCl, 0.5% 
Nonidet P-40, 1 mM PMSF and inhibitors cocktail (Sigma) and incubated 
on ice for 10 min. Nuclei were precipitated by microcentrifugation at 
2000 X g for 5 min at 4°C, resuspended in nuclear lysis buffer containing 
50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.8% sodium dodecyl sulphate 
(SDS), 1 mM PMSF and inhibitors cocktail (Sigma), and then incubated 
on ice for 10 min. Samples were broken by sonication into chromatin 
fragments of an average length of 500/1000 bp and then microcentrifuged 
at 16,000 X g for 10 min at 4°C. The sonicated cell supernatant was 
diluted 8-fold in ChIP Dilution Buffer containing 0.01% SDS, 1.1% 
Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.0), and 167 mM 
NaCl, and precleared by adding Salmon Sperm and conjugating protein at 
equimolar concentration for 90 min at 4°C. Precleared chromatin from 1 
X 106 cells was incubated with 1 μg of polyclonal antibody or no 
antibody and rotated at 4°C for 16h. Immunoprecipitates were washed 
five times with RIPA buffer containing 10 mM Tris-HCl (pH 8.0), 1 mM 
EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 140 mM 
NaCl, and 1 mM PMSF; twice with LiCl buffer containing   0.25 M LiCl, 
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1% Nonidet P-40, 1% Na-deoxycholate, 1 mM EDTA, 10 mM Tris-HCl 
(pH 8.0), and then three times with TE (10 mM Tris-HCl pH 8.0; 1 mM 
EDTA). Before the first wash, the supernatant from the reaction lacking 
primary antibody was saved as total input of chromatin and was 
processed with the eluted immunoprecipitates beginning at the cross-link 
reversal step. Immunoprecipitates were eluted by adding 1% SDS, 0.1 M 
NaHCO3 and reverse cross-linked by addition of NaCl to a final 
concentration of 200 mM and by heating at 65°C for at least 4h. 
Recovered material was treated with proteinase K, extracted with phenol-
chloroform-isoamyl alcohol (25:24:1) and precipitated. The pellets were 
resuspended in 30 μl of TE and analyzed by PCR using specific primers 
for the analyzed regions. The input sample was resuspended in 30 μl of 
TE and diluted 1:10 before PCR.  
For ReChIP assay, immunoprecipitates with the first antibody were eluted 
in 50 ml of DTT 10 mM, diluted 10-fold in ChIP Dilution Buffer 
supplemented with protease inhibitors, and immunoprecipitated with the 
second antibody. Following immunoprecipitation, samples are processed 
as described above for ChIP assay and eluted DNA amplified by PCR 
with specific oligos. 
 
MNase (Micrococcal Nuclease) Protection assay. Nuclei were isolated 
from 108 Hela, HelaHNF4, HepG2 and HepG2sh cells. Isolated nuclei  
were suspended in 1 ml of wash buffer (10 mM Tris-HCl, pH 7.4, 15 mM 
NaCl, 50 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, and 8.5% 
sucrose) and digested with 120U of micrococcal nuclease (MNase;  
Worthington Biochemical, Freehold, NJ) for 30 min at 37°C. Reactions 
were stopped by the addition of 100 µl of 5 M NaCl and 100 µl of stop 
solution (10% SDS, 125 mM EDTA, and 1 mg/ml proteinase K) at 50°C 
for 3 h. Genomic DNAs were separated on a 1.5% agarose gel. The bands 
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corresponding to mononucleosome (150 bp) were cut with a clean blade, 
and DNAs were isolated from the excised gel slice using the GFX PCR 
purification Kit (GE Healthcare). The purified DNA was quantified and 
identified on an agarose gel again and subsequently amplified by PCR 
using the N1F/R, N2F/R and Ex-1 F/R couples of primers.  
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CHAPTER 3 
Molecular cloning and characterization of the human PED/PEA-15 
promoter reveals its antagonistic regulation by HNF-4alpha and COUP-
TFII 
 
RESULTS 
 
Localization of the promoter activity within the 5’-flanking region of 
the PED/PEA-15 gene. 
To verify whether the proximal 5’-flanking region of the PED/PEA-15 
gene contains a functional promoter, reporter gene assays were performed 
in human embryonic kidney (HEK 293) and cervical carcinoma (Hela) 
cell lines. A 2 Kb PCR product, containing the proximal 5’-flanking 
region, the transcription start site and 58 bp of exon 1, was cloned 
upstream to a promoterless luciferase reporter gene (fragment -1942/+58, 
pPED2000). Three independent clones were tested showing similar 
promoter activity both in the Hela and HEK 293 cells (data not shown). 
Next, the pPED2000 plasmid was used as a template to generate 
progressive deletion fragments of the PED/PEA-15 5’-flanking region, 
which were analyzed for promoter activity (Fig.7). The constructs were 
transfected in Hela and HEK 293 cell lines and luciferase activity was 
measured after 48h. Significant transcriptional activity compared to the 
basal luciferase activity was obtained in both cell lines with all of the 
deletion constructs encompassing the PED/PEA-15 promoter region -
1942/-39. Indeed, the shortest -39/+58 fragment still has a significantly 
higher luciferase activity compared to the empty vector, suggesting that 
all the basal promoter activity is contained in the very proximal 5’-
flanking region. Since luciferase activity significantly declines from -230, 
it is possible that the minimal promoter is located within this sequence 
(Fig.7). Truncation of promoter at an upstream region between -1042 and 
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-542 and between -419 and -309 produced a decrease in the PED/PEA-15 
transcriptional activity, indicating that these regions contain positive 
regulatory elements of the basal promoter function. A further deletion 
between -309 and -230 revealed the presence of a potential transcription 
silencer. 
 
Figure 7 – Characterization of the promoter activity of the PED/PEA-15 5’ 
flanking region. The PED/PEA-15 5’ flanking fragments were cloned upstream to a 
promoterless luciferase reporter gene in the pGL3 Basic vector as described under 
Materials and Methods. Hela (black bars) and HEK293 cells (grey bars) were then 
cotransfected with 3 mg of the construct DNAs (or 3 mg of the promoterless pGL3 
Basic vector DNA) and 1 mg of the pRSVb-gal vector DNA. Luciferase activity was 
assayed as described under Materials and Methods and is presented as increase above 
the activity measured with the pGL3 Basic vector. The results are presented as the 
means (normalized for b-galactosidase activity) ± SD of four independent 
experiments each performed in quadruplicate. Asterisks denote statistically significant 
differences (p < 0.001). 
 
Regulation of the PED/PEA-15 transcriptional activity by HNF-4alpha. 
In silico analysis of the PED/PEA-15 promoter region revealed the 
presence of a 5’-GTCATCCAAAGGTCAAA-3’ sequence located 
between the -419/+58 and -309/+58 fragments. This sequence closely 
resembles the HNF-4alpha responsive element (HRE) (44-45), suggesting 
the presence of an HNF-4alpha binding site in the promoter of the 
PED/PEA-15 gene. To address the role of HNF-4alpha in PED/PEA-15 
promoter transcriptional activity, we co-transfected the  -419/+58 
PED/PEA-15 promoter-luciferase construct (pPED477) together with an 
HNF-4alpha expression vector, (pCDNA3/HNF-4alpha) into Hela cells, 
which feature low levels of the endogenous HNF-4alpha. As shown in 
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Fig.8A, HNF-4alpha reduces the reporter gene activity in a dose-
dependent manner. This effect is specific, as it is lost when the cells are 
transfected with a vector containing the mutagenized HNF-4alpha 
binding sequence (pPED477mut) and a 5’ deletion construct lacking the 
HNF-4alpha site (pPED210) (Fig.8B).  
 
 
 
 
Figure 8 – Regulation of PED/PEA-15 promoter activity by HNF-4alpha. (A) 
Hela cells were co-transfected with 2 μg of the pPED477 PED/PEA-15 promoter-
luciferase construct and the indicated amounts of the pCDNA3/HNF-4alpha 
expression vector. (B) Alternatively, the cells were co-transfected with the pPED477, 
the pPED477mut or the pPED210 PED/PEA-15 promoter luciferase constructs and 
0.8 μg of the pCDNA3/HNF-4alpha expression vector. Luciferase activities were 
normalized for those of β-galactosidase and are presented as the means ± SD of four 
independent experiments each performed in quadruplicate. Asterisks denote 
statistically significant differences (* p < 0.05; *** p < 0.001). 
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Consistent with these luciferase assays, Real Time PCR assay on total 
RNA extracted from HNF-4alpha transfected Hela cells confirmed a 2-
fold decrease in PED/PEA-15 expression levels (Fig.9A). Same analysis 
was performed by Western blot with similar results: as shown in Fig.9B, 
the levels of PED/PEA-15 protein decreases in HNF-4alpha transfected 
Hela cells. Moreover, we observed an inverse correlation between 
PED/PEA-15 and HNF-4alpha protein levels in different cell types. In 
fact, HepG2 cells present well detectable levels of endogenous HNF-
4alpha and low levels of PED/PEA-15, while the opposite is observed in 
the Hela and HEK 293 cells both of which show low levels of HNF-
4alpha and high levels of PED/PEA-15 (Fig.9C).  
Overall, our results indicate that HNF-4alpha negatively regulates 
PED/PEA-15 gene expression.  
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Figure 9 – Correlation between PED/PEA-15 and HNF-4alpha levels. (A) Hela 
cells were transfected with 0.8 μg of the pCDNA3/HNF-4alpha expression vector. 
PED/PEA-15 mRNA levels were then quantitated by RT-PCR. Data were normalized 
for β-actin mRNA and are expressed as % decrease vs. control (untransfected cells). 
(B) Hela cells were transfected with the indicated amounts of the pCDNA3/HNF-
4alpha vector DNA. The cells were then solubilized and Western blotted with 
PED/PEA-15 antibodies followed by reblotting with HNF-4alpha antibodies. (C) 
Lysates from Hela, HEK293 and HepG2 cells (40 μg protein/sample) were analyzed 
by Western blotting with PED/PEA-15 antibodies followed by reblotting with HNF-
4alpha and actin antibodies. All filters were revealed by ECL and autoradiography 
and quantitated by laser densitometry of the autoradiographs. Bars represent the 
means ± SD of three (B) and four (A) independent experiments. Asterisks denote 
statistically significant differences (* p < 0.05; *** p < 0.001). Representative blots 
are also shown. 
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HNF-4alpha binds the cis-acting element at position -335 to -320 in the 
PED/PEA-15 promoter. 
We next tested the ability of HNF-4alpha to bind the putative binding 
sequence in the PED/PEA-15 gene promoter. EMSA was performed 
using a probe containing the putative HNF-4alpha-binding site, 
designated HNF-4alpha RE element (Fig.10A). Whole cell extracts were 
obtained from Hela cells transfected either with an HNF-4alpha 
expression plasmid or a control vector. Incubation of HNF-4alpha-
transfected Hela cell extracts with the radiolabeled probe resulted in a 
strong band that was absent when the cells were transfected with the 
empty vector (lanes 2 and 1). Competition with unlabeled HNF-4alpha 
RE oligonucleotide abolished this band (lane 3). In contrast, increasing 
amounts of the mutated HNF-4alpha RE probe added to the binding 
reactions competed for HNF-4alpha binding to the probe encompassing 
the wild-type sequence much less efficiently (lanes 4-6). These data 
indicate that in vitro HNF-4alpha binds to the PED/PEA-15 HNF-4alpha 
RE site at – 335 to –320 position.  
Occupancy of the PED/PEA-15 promoter by HNF-4alpha in living cells 
was further analyzed by Chromatin Immunoprecipitation (ChIP) 
experiment. Wild-type HepG2 cells which show well detectable levels of 
this transcription factor, were used. Chromatin DNA was precipitated 
using either the anti-HNF-4alpha or anti-HA antibodies as negative 
control, and the sequence encompassing the HNF-4alpha consensus 
binding site was amplified using specific primers. As shown in Fig.10B, 
precipitation with HNF-4alpha (lane 2a) but not HA (lane 3a) antibodies 
enabled amplification, indicating occupation of the PED/PEA-15 
promoter by HNF-4alpha. As a positive control, a 145-bp fragment 
containing the HNF-4alpha response element of the UGT1A9 promoter 
was also amplified from genomic DNA precipitated with the HNF-4alpha 
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antibody (lane 2b) [90]. Consistently, PCR amplification with 
oligonucleotides for β-GLOBIN (negative control) did not show any 
signal. Same results were also obtained with primary human hepatocytes 
(Fig.10B).  
 
 
 
Figure 10 – HNF-4alpha binding to the PED/PEA-15 gene promoter. (A) 
EMSA.Whole cell extracts from Hela cells transfected with either the empty plasmid 
(lane 1) or the HNF-4alpha expression vector (lanes 2-6) were incubated with the 32P-
labelled HNF-4alpha RE probe. Incubation occurred in the absence (lanes 1-2) or the 
presence of either a 4-fold molar excess of unlabelled HNF-4alpha RE probe (HREwt; 
lane 3) or 2-, 4-, 10-fold molar excess of unlabelled HNF-4alpha RE mutated 
oligonucleotides (HRE mut; lanes 4-6). Proteins were separated on a non-denaturing 
polyacrylamide gel and revealed by autoradiography. The autoradiograph shown is 
representative of four independent experiments. (B) ChIP assay. Soluble chromatin 
was prepared from HepG2 cells and human primary hepatocytes as described under 
Materials and Methods and immunoprecipitated with either HNF-4alpha (lanes 2 and 
5) or HA antibodies (lanes 3 and 6). Total (INPUT; lanes 1 and 4) and 
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immunprecipitated DNAs were then amplified using primer pairs covering HNF-
4alpha RE on the PED/PEA-15 (a) and the UGT1A9 promoters (b; positive control) or 
the β-GLOBIN (c; negative control). The photographs shown are each representative 
of three independent experiments. 
 
To further assess the direct role of HNF-4alpha on PED/PEA-15 
expression, we used an RNAi-mediated approach. Transfection of HepG2 
cells with HNF-4alpha specific sh-RNA clones caused a decrease of 
HNF-4alpha mRNA to 20% of the endogenous levels (Fig.11A). In the 
same cells, a parallel increase of PED/PEA-15 mRNA and protein levels 
were observed (Fig.11B and C), supporting the important role of HNF-
4alpha in controlling PED/PEA-15 expression. 
 
 
Figure 11 – The effect of RNAi-mediated silencing of HNF-4alpha on PED/PEA-
15 gene expression in HepG2 cells. HepG2 cells were transiently transfected with 
two HNF-4alpha-specific shRNA clones (Cl. a, b). 48 h upon transfection, total RNAs 
were extracted form transfected and non-transfected cells (NT). HNF-4alpha (A) and 
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PED/PEA-15 (B) mRNA levels were then quantitated by RT-PCR. Bars represent 
values normalized for β-ACTIN mRNA. (C) HepG2 cells were transiently transfected 
with the HNF-4alpha shRNA (Cl.b). After 48 h, transfected and non transfected cells 
were solubilized and lysates Western blotted with antibodies toward HNF-4alpha, 
PED/PEA-15 or β-ACTIN. Filters were revealed by ECL and autoradiography, 
followed by densitometric analysis of the autoradiographs. Bars represent the means ± 
SD of four (A,B) and three (C) independent experiments. Asterisks denote statistically 
significant differences. A representative blot is shown in the left panel of (C). 
 
PED/PEA-15 gene transcription is activated by COUP-TFII. 
COUP-TF antagonizes HNF-4alpha-dependent gene expression [44; 45; 
91-93]. We have therefore hypothesized that COUP-TFs may also 
regulate PED/PEA-15 transcription. To this aim, the pPED477 luciferase 
construct containing the HRE was transfected in Hela cells together with 
the COUP-TFII expression vector (pCMV6-XL5COUP-TFII). As shown 
in Fig.12A, COUP-TFII produced an activation of the reporter gene in a 
dose dependent manner (Fig.12A). This effect did not occur in cells 
transfected with a pPED477mut containing the mutagenized HNF-4alpha 
binding site and the 5’ deletion construct lacking this site (pPED210) 
(Fig.12B), indicating that COUP-TFII activates the human PED/PEA-15 
promoter through the HNF-4alpha-responsive element. Real Time PCR 
assay and western blot analysis on COUP-TFII transfected Hela cells also 
confirmed the increase in PED/PEA-15 expression level (Fig.12C and D).  
As shown in Fig.12E, COUP-TFII specifically bound the HRE on 
PED/PEA-15 promoter in native Hela cells. At variance, COUP-TFII 
binding to the HRE was almost undetectable in the HepG2 cell lines 
which express HNF-4alpha at higher levels.  
These data clearly indicate that COUP-TFII is involved in the regulation 
of Ped/Pea-15 expression and, in particular, it activates Ped/Pea-15 
expression by binding the HNF-4alpha responsive element on its 
promoter.  
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Figure 12 – COUP-TFII action on PED/PEA-15 expression. (A) Hela cells were 
transiently transfected with 2 μg of the pPED477 PED/PEA-15 promoter-luciferase 
construct, the indicated amounts of the pCMV6-XL5COUP-TFII plasmid and 1 mg of 
the pRSV-bgal plasmid (transfection efficiency control). Alternatively (B), the cells 
were transfected with the pPED477, the pPED477mut or the pPED210 PED/PEA-15 
promoter luciferase constructs, together with 0.4 mg of the COUP-TFII expression 
vector and 1 mg of the pRSV-bgal expression plasmid. Luciferase activity was 
assayed as described under Materials and Methods and normalized for b-
galactosidase. (C) Hela cells were transfected with 0.4 mg of the COUP-TFII 
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expression vector. Upon 48 h, PED/PEA-15 mRNA levels were quantitated by RT-
PCR and normalized for b-ACTIN mRNA. Bars represent the means ± SD of three 
(A,B) and four (C) independent experiments, each in quadruplicate. All data are 
expressed as increases above values in control cells. (D) Hela cells were transfected 
with 0.4 mg of the COUP-TFII expression plasmid, solubilized and proteins (40 
mg/sample) were separated by PAGE and analyzed by Western blotting with COUP-
TFII and PED/PEA-15 antibodies, as indicated. Filters were revealed by ECL and 
autoradiography and autoradiographs subjected to densitometry. Bars represent the 
means ± SD of three independent experiments. A representative experiment is shown 
in the left panel. Asterisks denote statistically significant differences (* p < 0.05; ***p 
< 0.001). (E) HepG2 and Hela cells were cross-linked with 1% formaldehyde and 
subjected to Chip assays using COUP-TFII (lanes 3) and HA antibodies (lanes 2; 
negative control). Total (lane 1; INPUT) and immunoprecipitated DNAs were 
amplified using primers covering the HNF-4a RE in the PED/PEA-15 gene. The 
photographs shown are representative of at least three independent experiments. 
 
COUP-TFII opposes HNF-4alpha repression of PED/PEA-15 gene 
expression. 
Since HNF-4alpha and COUP-TFII appear to bind the same response 
element on the promoter of PED/PEA-15 gene, we hypothesized that 
these two proteins compete with each other for binding. Therefore, 
transient transfection assays were performed with the pPED477 reporter 
construct and various combinations of HNF-4alpha and COUP-TFII 
expression vectors. As shown in Fig.13A, HNF-4alpha repression of the 
pPED477 construct expression in Hela cells can be completely overcome 
by increasing amounts of COUP-TFII. Conversely, transactivation by 
COUP-TFII was repressed by increasing amounts of HNF-4alpha, 
indicating that COUP-TFII antagonizes repression of the PED/PEA-15 
gene by HNF-4alpha. Moreover, ChIP experiments in HepG2 cells 
demonstrate that HNF-4alpha binding to the PED/PEA-15 promoter is 
reduced by increasing amounts of COUP-TFII (Fig.13B), while the 
opposite was obtained in Hela cells in which COUP-TFII binding to the 
PED/PEA-15 promoter is antagonized by increasing amount of HNF-
4alpha (Fig.13C).  
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Figure 13 – Antagonistic effects of HNF-4alpha and COUP-TFII on PED/PEA-
15 promoter. Hela cells were transiently transfected with 2 μg of the pPED477 
PED/PEA-15 promoter-luciferase construct alone (open bar) or in combination with 
the indicated amounts of the pCMV6-XL5COUP-TFII and the pCDNA3/HNF-4alpha 
plasmids. Luciferase activity was assayed and normalized as described under 
Materials and Methods. Bars represent the mean ± SD of three independent 
experiments. Asterisks denote statistically significant differences (p < 0.001). (B, C) 
ChIP assays. Soluble chromatin was prepared from HepG2 (B) and Hela (C) cell lines 
as described under Materials and Methods and immunoprecipitated with HNF-4alpha, 
COUP-TFII and HA antibodies. Total (INPUT) and immunoprecipitated DNAs were 
amplified using primer pairs covering HNF-4alpha RE on the PED/PEA-15 promoter. 
The photographs shown are representative of three independent experiments. 
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CHAPTER 4  
HNF-4alpha directs histone deacetylation and methylation to silence 
Ped/Pea-15 expression in human cultured hepatocytes 
 
RESULTS 
 
HNF-4alpha expression results in nucleosome assembly at the 
promoter of  PED/PEA-15  
We have already shown that HNF-4alpha inhibits PED/PEA-15 
expression by binding the HRE and, at least in part, by competing for the 
binding with COUP-TFII. 
By the way, the molecular mechanism by which HNF-4alpha exerts its 
action on PED/PEA-15 expression is still unclear. 
As an attempt to clarify this mechanism, we analysed the region 
immediately downstream the HRE on PED/PEA-15 promoter by using 
the free available software RECON [94] which calculates the nucleosome 
formation potential of a given DNA sequence. We localized two potential 
nucleosomes on PED/PEA-15 promoter, and we called them NUC81 
(N1) and NUC208 (N2). N1 is closed to the HRE, whilst N2 overlaps the 
transcription start site of the gene (Fig.14A).  
To further validate bioinformatic results, we examined protein occupancy 
at PED/PEA-15 promoter both in wild-type Hela and HepG2 cells and in 
HelaHNF and HepG2sh cells as well. 
As previously described, Hela and HepG2 cells significantly differ from 
each other in Ped/Pea-15 mRNA levels, with Hela cells having higher 
PED/PEA-15 expression than HepG2 cells. Furthermore, in Hela cells 
HNF-4alpha is barely absent and not bound to the HRE differently from 
HepG2 cells which show high HNF-4alpha expression and binding. Hela 
cells were transfected with a full-length HNF-4alpha cDNA (HelaHNF 
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cells) to silence PED/PEA-15 expression whilst PED/PEA-15 expression 
was restored in HepG2 cells, by silencing HNF-4alpha with a specific 
shRNA (HepG2sh cells). 
To analyse protein occupancy at PED/PEA-15 promoter we used a 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) assay. 
Once protein and DNA are crosslinked, chromatin is prepared and 
sheared by sonication. Then protein-free DNA is then purified by a 
phenol/chloroform extraction, recovered in the aqueous phase and 
subjected to PCR amplification with specific primers. 
In these cell lines we performed FAIRE followed by end-point PCR using 
specific primers  spanning the N1 (N1F/R) and N2 (N2 F/R) regions, as 
schematically depicted in Fig.14A. As shown in Fig.14B protein/DNA 
complexes from each cell type were sonicated at comparable levels (0.1 – 
0.5 Kb) and, in these conditions, N1 and N2 regions were specifically 
occupied in HepG2 and HelaHNF cells (Fig. 14C), whilst these regions 
were free of proteins in Hela and HepG2sh cells.  
A preparation of input DNA, obtained by decrosslinking protein/DNA 
complexes, is included as an internal control of total cellular DNA. 
These data clearly show that HNF-4alpha binding to the HRE directs 
protein assembly at the promoter of PED/PEA-15. 
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Figure 14 – Protein Occupancy at the promoter of Ped/Pea-15. (A) Schematic 
representation of nucleosome positioning at the promoter region of the Ped/Pea-15 
gene. (B) Protein and DNA from each of the four cell types were crosslinked with 1% 
Formaldehyde and obtained chromatin was sheared by sonication. As shown in the 
picture, after 6 strokes of sonication chromatin was sheared at comparable levels in all 
cell types with DNA fragments ranging from 0.1 to 0.5 kilobases. (C) DNA recovered 
in the aqueous phase by phenol/chloroform extraction was subjected to end-point 
PCR with N1F/R and N2F/R primer pairs to analyse protein occupancy at these 
regions. As shown, only in Hela and HepG2sh cells, which have high Ped/Pea-15 
expression levels and low HNF-4alpha binding, N1 and N2 regions are free of 
proteins, whilst in HelaHNF and HepG2 cells, having high HNF-4alpha binding and 
low Ped/Pea-15 expression levels, no PCR product is obtained for N1 and N2 regions 
indicating they are occupied by proteins. A preparation of input DNA, obtained by 
decrosslinking protein/DNA complexes, is included as an internal control of total 
cellular DNA.   
 
To further confirm FAIRE results and assess the presence of nucleosomes 
on PED/PEA-15 promoter, we performed MNase Protection Assay on 
chromatin digested up to mononucleosomes, as representatively shown 
by the picture in Fig.15A. Mononucleosomal DNA was then extracted 
from the agarose gel and subjected to end-point PCR with specific 
primers, so that PCR product was visible only for DNA regions protected 
from enzymatic digestion. As shown in figure 15B, both N1 and N2 
regions are protected from MNase digestion in HelaHNF as well as in 
HepG2 cells where HNF-4alpha is bound to the HRE, whilst they are 
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sensitive to MNase in Hela and HepG2sh cells where HNF-4alpha is not 
bound to the HRE. These results strongly suggest that HNF-4alpha 
directs nucleosome assembly on PED/PEA-15 promoter once bound to 
the HRE. A preparation of undigested chromatin is included as an internal 
control of DNA quality, whilst the Ex-1 region is used as a control of 
MNase digestion because it represents the exon-1 of PED/PEA-15 gene 
which is never protected from the enzymatic activity as shown in 
Fig.15C. 
 
Figure 15 – HNF-4alpha dependent nucleosome assembly at the promoter of 
Ped/Pea-15. (A) Chromatin obtained from Hela, HelaHNF, HepG2 and HepG2sh cells 
is digested with 120 U of MNase for 30’ to obtain mononucleosomes. Once separated 
on an agarose gel, mononucleosomal DNA (indicated by the arrow in the picture) is 
purified and used as template for PCR reaction with specific oligos. (B) N1 and N2 
regions are protected from MNase digestion in cells which have high levels of HNF-
4alpha expression and binding to the HRE, as happens for HelaHNF and HeopG2 cells. 
By contrary, they are not protected in Hela and HepG2sh cells which have very low 
levels of HNF-4alpha expression and binding to the HRE. (C) Analysis of the exon-1 
region is included as a control of MNase digestion. 
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HNF-4alpha expression results in histone deacetylation and 
methylation of the PED/PEA-15 promoter 
We next focused on the influence of HNF-4alpha on the epigenetic state 
of the nucleosomes on PED/PEA-15 promoter. We analysed epigenetic 
marks characteristic of transcriptional activation and repression both in 
wild-type Hela and HepG2 cells and in HelaHNF and HepG2sh cells as 
well. Histone modifications were analysed by ChIP assays followed by 
Real-Time PCR for the N1 region and end-point PCR for the N2 region. 
Consistently with the reduced expression of PED/PEA-15 gene in HepG2 
and HelaHNF cells compared with Hela and HepG2sh cells respectively, 
general acetylation of histone H3 (AcH3) was decreased at both N1 and 
N2 (Fig.16A).  
Similarly, there was a reduction, in the presence of HNF-4alpha, of di-
methylated histone H3 at lysine 4 (H3K4), a mark usually associated with 
active genes [95], at both N1 and N2 regions (Fig.16B), and an 
enrichment in the di-methylation of histone H3 at lysine 9 (H3K9), a 
mark characteristic of repressed gene promoters [96]. In particular, 
H3K9, involved in transcriptional repression in euchromatic regions [97], 
was increased in HNF-4alpha expressing cells at both N1 and N2. 
We conclude that HNF-4alpha expression and binding to the HRE results 
in a deacetylation of the histone H3 and in an enrichment of repressive 
histone modifications, leading to a reduction of PED/PEA-15 gene 
expression. 
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Figure 16 – HNF-4alpha dependent histone modifications at the promoter of the 
PED/PEA-15 gene. Chromatin obtained from Hela, HelaHNF, HepG2 and HepG2sh 
cells is sheared by sonication and subjected to immuno-precipitation with antibodies 
directed against the acetylated Lys9 and Lys14 on histone H3 (A), the di-methylated 
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Lys4 on histone H3 (B) and the di-methylated Lys9 on histone H3 (C). The DNA 
eluted and purified from the immuno-complexes is then analyzed by Real-Time PCR 
or end-point PCR. A preparation of input DNA, obtained by decrosslinking 
protein/DNA complexes from non immunoprecipitated lysate, is included as an 
internal control of total cellular DNA, and a NoIP sample is included as a negative 
control. Expression of HNF-4alpha and its binding to the HRE reduces markers of 
active expression on PED/PEA-15 promoter and enriches markers of inactive 
chromatin, thus leading to a reduction in Ped/Pea-15 expression levels.  
*** stands for p < 0.001 
 
Restoration of PED/PEA-15 expression in HepG2 cells by treatment 
with 5-Aza-dC and TSA 
To examine whether PED/PEA-15 silencing in HepG2 cells could be 
restored, we treated HepG2 cells for 24h with 10μM of the  DNA 
methylation inhibitor 5-deoxy-Aza-Cytidine (5-Aza-dC) [98], or 330nM 
of the histone deacetylase inhibitor, Trichostatin A (TSA), [99]. The two 
drugs were also used in combination to evaluate a potential synergism 
between their different mechanisms of action. 
After treatment, cells were harvested and analysed for HNF-4alpha and 
PED/PEA-15 expression compared with untreated cells. Real-Time RT-
PCR revealed an increase in HNF-4alpha and PED/PEA-15 expression 
upon 5-Aza-dC and TSA treatment compared with untreated cells 
(Fig.17A and B), indicating that DNA methylation and histone 
deacetylation are both involved in the control of their expression.  
We next examined the possibility that the demethylation and the  
hyperacetylation of PED/PEA-15 promoter following 5-Aza-dC and TSA 
treatment may affect HNF-4alpha binding thus leading to an increase in 
PED/PEA-15 expression. As shown in Fig.17C, HNF-4alpha binding to 
the HRE on PED/PEA-15 promoter was unaffected (or slightly increased) 
after 5-Aza-dC and TSA treatment consistently with the increasing 
expression. 
To decipher whether DNA methylation and epigenetic modifications in 
PED/PEA-15 promoter are related, we examined histone H3 acetylation 
and methylation upon treatments, by ChIP assay. As shown in Fig.17D, 
 46
histone H3 was much more acetylated on both N1 and N2 upon treatment 
with TSA, alone or in combination with 5-Aza-dC, compared with 
untreated cells. No significant differences were observed with 5-Aza-dC 
alone. Consistently, the lysine 9 on histone H3 of both N1 and N2 was 
less methylated in HepG2 cells treated with TSA, alone or in combination 
with 5-Aza-dC, compared with untreated cells. Once again no differences 
were observed with 5-Aza-dC alone. 
These data strongly suggest that DNA methylation and histone 
modifications are two independent mechanisms potentially involved in 
the regulation of PED/PEA-15 expression in HepG2 cells. It is even clear 
that HNF-4alpha functions as a scaffold protein to recruit a corepressor 
with histone deacetylase activity to silence PED/PEA-15 expression in 
HepG2 cells. 
 
Figure 17 – 5-Aza-dC and TSA treatment restores Ped/Pea-15 expression in 
HepG2 cells. HepG2 cells were treated for 24h with 10μM of 5-Aza-dC and/or 
330nM of TSA to try to restore PED/PEA-15 expression. After treatment, cells were 
harvested to evaluate both HNF-4alpha expression and binding to the HRE (A,C) and 
PED/PEA-15 expression and histone modifications of its promoter in terms of general 
acetylation of histone H3 and di-methylation of the Lys9 of histone H3 (B,D). As 
shown in the figure, treatments increase both HNF-4alpha and PED/PEA-15 
expression. In particular, TSA treatment has a strong effect on H3 acetylation and H3 
Lys9 di-methylation of the PED/PEA-15 promoter, indicating that HNF-4alpha acts 
by recruiting a corepressor complex with histone deacetylase (HDAC) activity.  
*** stands for p < 0.001. 
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HNF-4alpha targets repressive enzymes to the PED/PEA-15 promoter 
leading to its tight packaging and inhibition of transcription 
Given that HNF-4alpha expression and binding to the HRE on PED/PEA-
15 promoter leads to a decrease in histone acetylation and to a subsequent  
increase in the di-methylation of the Lys9 on histone H3, we next 
investigated the binding of histone-modifying enzymes to the PED/PEA-
15 promoter, in the presence and absence of HNF-4alpha. 
Recent data in literature show that HNF-4alpha interacts with the Silencer 
Mediator of Retinoic acid and Thyroid hormone receptor (SMRT) [100].  
SMRT is a corepressor complex with HDAC activity, which is recruited 
by hormone-free receptors, such as thyroid hormone and retinoic acid 
receptors, and mediates histone deacetylation to silence the expression of 
target genes. 
Using ChIP assay, we demonstrated an increase in the binding of the 
SMRT corepressor complex to the HRE in HepG2 cells, compared to 
Hela cells (Fig.18A). Importantly, recruitment of this repressive enzyme 
was entirely dependent on the presence of HNF-4alpha whilst its 
expression was not affected by the expression of HNF-4alpha, as shown 
in figure 18B where relative mRNA levels of SMRT are comparable in 
Hela and HepG2 cells, differently from HNF-4alpha, which is clearly 
much more expressed in HepG2 rather than in Hela cells (Fig.18B).  
These data clearly indicate that SMRT recruitment was strictly dependent 
on HNF-4alpha and was not a reflection of its relative expression levels. 
To further assess the role of HNF-4alpha in the recruitment of SMRT to 
the promoter of Ped/Pea-15, we evaluated the assembly of HNF-
4alpha/SMRT complex on the HRE by ReChIP assay in our cellular 
models. Briefly, sheared chromatin from each cell type was first 
immunoprecipitated with the HNF-4alpha antibody and the immuno-
complex was then subsequently immunoprecipitated with the SMRT 
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antibody. The DNA purified from the immuno-complex was amplified 
with the primers for the HRE. As you can see from the figure 18C the 
formation of the HNF-4alpha/SMRT complex is dependent on HNF-
4alpha binding, because it is increased both in HelaHNF and HepG2 cells 
when compared with Hela and HepG2sh cells respectively. We further 
demonstrated the interaction between HNF-4alpha and SMRT by co-
immunoprecipitation followed by western blot assay. Briefly, nuclear 
extracts from each cell type were immunoprecipitated with the SMRT 
antibody and then the immunocomplexes blotted with the HNF-4alpha 
antibody. Once again, the amount of SMRT, being comparable in all cell 
lines, is not dependent upon HNF-4alpha expression whilst the interaction 
between them is completely dependent on HNF-4alpha expression 
because this interaction is much stronger in HelaHNF and in HepG2 cells 
compared with Hela and HepG2sh cells respectively, as shown in figure 
18D. 
Our data clearly demonstrate that HNF-4alpha interacts with and recruits 
SMRT to PED/PEA-15 promoter and this can lead to the silencing of 
Ped/Pea-15 expression via deacetylation and packaging of the core-
promoter of the gene.  
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Figure 18 – HNF-4alpha interacts with and recruits SMRT to Ped/Pea-15 
promoter. (A) Chromatin from Hela and HepG2 cells was immunoprecipitated with 
the SMRT antibody and eluted DNA amplified with the primers for the HRE. As 
shown, the binding of SMRT is much more stronger in HepG2 cells which have high 
levels of endogenous HNF-4alpha. Rather than the recruitment to the HRE, SMRT 
expression is not dependent on HNF-4alpha expression. (B) 1 μg of total cellular 
RNA from Hela and HepG2 cells was reverse transcribed to obtain cDNA and 12.5 ng 
of cDNA was used in the RT-PCR with HNF-4alpha and SMRT specific primers. As 
shown in the picture, Hela and HepG2 cells have comparable levels of SMRT mRNA 
even though HepG2 cells have higher HNF-4alpha levels. (C) Sheared chromatin 
from Hela, HelaHNF, HepG2 and HepG2sh cells was sequentially immunoprecipitated 
with HNF-4alpha and SMRT antibodies. Ped/Pea-15 promoter occupancy was then 
quantified by Real-Time PCR with primers for the HRE and after normalization over 
input DNA, used as a control of total cellular DNA. As shown in the figure, the 
formation of the HNF-4alpha/SMRT complex is dependent on HNF-4alpha 
expression and binding. (D) Nuclear extracts from Hela, HelaHNF, HepG2 and 
HepG2sh cells  were immunoprecipitated with the SMRT antibody and the 
immunocomplexes separated on a SDS-PAGE and blotted with HNF-4alpha antibody, 
showing a much strong interaction between HNF-4alpha and SMRT in HelaHNF and 
HepG2 cells which have high levels of HNF-4alpha expression and binding. 
*** stands for p < 0.001  
 
Histone deacetylation has been shown to induce transcriptional repression 
of genes at euchromatic regions [73] by mediating the tight packaging of 
core-promoters.  
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To go further insight this mechanism in the case of PED/PEA-15, we 
evaluated the packaging of the PED/PEA-15 promoter by ReChIP 
experiments using H3K9 antibody in the first ChIP and HNF-4alpha or 
SMRT antibodies in the second ChIP. As shown in Fig. 19, we were able 
to detect HNF-4alpha and SMRT together with H3K9 at both N1 and N2 
regions in HelaHNF and HepG2 cells compared with Hela and HepG2sh 
cells, where signals were barely undetectable. These evidences clearly 
indicate a HNF-4alpha-dependent packaging of the PED/PEA-15 
promoter. 
Taken together, our results lead us to conclude that HNF-4alpha 
selectively targets SMRT to the PED/PEA-15 promoter resulting in its 
tight packaging and repression of gene expression. 
 
Figure 19 – HNF-4alpha mediates the packaging of the PED/PEA-15 promoter. 
To evaluate the HNF-4alpha-dependent packaging of the PED/PEA-15 promoter, 
sheared chromatin from Hela, HelaHNF, HepG2 and HepG2sh cells was sequentially 
immunoprecipitated with the H3K9 and the HNF-4alpha or the SMRT antibodies and 
eluted DNA amplified with primers N1F/R and N2F/R. As shown in the figure, both 
at the N1 and N2 regions, HNF-4alpha functions as a scaffold protein to recruit 
SMRT and induce the tight packaging of the PED/PEA-15 promoter. All the effect 
observed are completely dependent upon HNF-4alpha expression and binding to the 
HRE. *** stands for p < 0.001 
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Inhibition of SMRT expression restores Ped/Pea-15 expression 
reverting the inhibitory effect of HNF-4alpha 
As already demonstrated in this work that the SMRT corepressor interacts 
with HNF-4alpha on both HRE and nucleosomes of the Ped/Pea-15 
promoter. 
To assess the contribution of SMRT to the HNF-4alpha dependent 
repression of PED/PEA-15 expression, HepG2 cells were transfected 
with a SMRT selective siRNA (panS), or a non-specific control (Con.) as 
previously reported by Peterson T.J. et al. [102].  
SMRT and PED/PEA-15 expression were measured as both mRNA and 
protein levels (Fig.20A and 20B) showing that selective  depletion of 
SMRT significantly increased PED/PEA-15 expression. ChIP 
experiments from both panS and Con. transfected cells show that HNF-
4alpha binding to the HRE was not affected by panS, whilst SMRT 
binding to the HRE as well as HNF-4alpha/SMRT interaction on 
PED/PEA-15 promoter was significantly reduced (Fig.20C). Furthermore 
we analyzed histone modifications at both N1 and N2 regions in panS and 
Con. transfected cells. As shown in Fig.20D, the general acetylation of 
histone H3 was strongly increased at both N1 and N2 regions, as 
expected after SMRT silencing, and, as a consequence of increased H3 
acetylation, H3K9 levels were significantly reduced. 
These data clearly indicate that SMRT plays a critical role in the HNF-
4alpha dependent inhibition of PED/PEA-15 expression as well as in the 
HNF-4alpha-dependent histone modifications at PED/PEA-15 promoter. 
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Figure 20 – SMRT silencing in HepG2 cells reverts the inhibitory effect of HNF-
4alpha on PED/PEA-15 expression. SMRT expression was silenced in HepG2 cells 
with a specific siRNA (panS) whilst a scrambled oligonucleotide (Con.) was used as a 
negative control. (A, B) SMRT and PED/PEA-15 mRNA and protein levels were 
evaluated after transfection showing a significant decrease in SMRT levels and a 
parallel increase in PED/PEA-15 levels as both mRNA and protein. (C) HNF-4alpha 
and SMRT binding to the HRE as well as the interaction between HNF-4alpha and 
SMRT on PED/PEA-15 promoter were evaluated after transfection by ChIP and 
ReChIP assays. As shown, whilst HNF-4alpha binding is not affected by SMRT 
silencing, SMRT binding as well as HNF-4alpha and SMRT interaction are 
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significantly reduced. (D) Consistently with the reduced formation of HNF-
4alpha/SMRT complex on PED/PEA-15 promoter, general acetylation of histone H3 
was significantly increased at both N1 and N2 regions and, as expected, the di-
methylated Lys9 on histone H3 was reduced. *** stands for p < 0.001 
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Chapter 5 
Discussion 
 
Several lines of evidence indicate that a multitude of concurrent 
alterations contribute to type 2 diabetes onset and progression [102-104]. 
Amongst these defects, the PED/PEA-15 gene has been found to be 
overexpressed in about 30% of individuals affected by type 2 diabetes 
and in their first degree relatives. Studies in cellular and animal models 
have shown a cause-effect relationship between the overexpression of 
PED/PEA-15 and impaired insulin action [7; 8; 19-21]. Thus, clarifying 
the mechanism of PED/PEA-15 transcriptional regulation will help 
understanding its abnormalities in type 2 diabetes. In the present study we 
have isolated and further characterized the PED/PEA-15 promoter region 
and we have identified cis-elements involved in the regulation of 
PED/PEA-15 human gene expression.  
The transcription start site of the PED/PEA-15 gene has already been 
mapped [105]. Analysis of the 5’ genomic sequence revealed that this 
gene lacks a TATA box and the first 600 bp flanking the transcription 
start region have a high GC content (64%), including several consensus 
Sp1 sites. These data are consistent with our results showing that the 
shortest 5’-flanking fragment spanning nucleotides -39/+58 contains all 
the elements necessary to achieve basal promoter activity.  
Deletion analyses showed that HNF-4alpha, a member of the steroid 
receptor class of transcription factors, binds to the -419/-309 fragment 
and represses PED/PEA-15 transcription through this region (Fig. 7, 8). 
Indeed transfection experiments of both an HNF-4alpha expression vector 
in Hela cells and an HNF-4alpha specific shRNA clone in HepG2 cells 
confirmed that this transcription factor is capable to repress PED/PEA-15 
expression both at the RNA and at the protein levels (Fig. 9 and 11). 
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EMSA and ChIP assays have further shown that the promoter site 
recognized by HNF-4alpha is located between nt -335 and -320 (Fig. 10). 
This element closely resembles the HNF-4alpha REs found in other genes 
and the GGGGCA A AGGTCA consensus HNF-4alpha binding site 
[106]. In addition we have shown that the same responsive element is 
recognized by COUP-TFII, another member of the orphan receptor 
family (Fig. 12). We found that COUP-TFII activates PED/PEA-15 gene 
expression by binding to the HRE (Fig. 12), while HNF-4alpha functions 
as a transcriptional repressor. The observation that these two transcription 
factors bind to the HRE in a mutually exclusive manner (Fig. 13) 
suggests that their mechanism of action involves direct competition at the 
level of DNA binding. Thus, transcription of the PED/PEA-15 gene is 
dependent upon the intracellular balance of these positive and negative 
regulatory factors. Competition for DNA binding has been described for 
other members of the steroid receptor superfamily which because of their 
highly related zinc finger DNA binding domains, can interact with 
overlapping or identical DNA elements. For example, estrogen and 
thyroid hormone receptors exert opposite regulatory effects via their 
competitive binding to the estrogen response element [107]. 
In certain cell types, where COUP-TFII occupies the HRE, transcription 
of PED/PEA-15 gene is enhanced while in other cell types, such as the 
hepatocytes, where HNF-4alpha is present in relatively abundant 
amounts, COUP-TFII is replaced by HNF-4alpha and PED/PEA-15 
transcription is repressed. At variance from the PED/PEA-15 gene, 
COUP-TFII most often serves as a transcriptional silencer [50] while 
HNF-4alpha is an activator [44]. There is also evidence, however, 
indicating that the function of many nuclear hormone receptors is 
dependent upon the actions of distinct receptor binding cofactors that 
differentially recognize occupied and unoccupied receptors [51-58]. 
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Indeed, nuclear receptors often interact with co-regulators affecting their 
target genes in a tissue- and gene-specific manner [108]. For instance, it 
has been reported that PGC-1alpha co-activates HNF-4alpha and induces 
CYP7A1 gene transcription during starvation in mice [109]. But Song et 
al. also demonstrated that Prox1, an early specific marker for liver and 
pancreas development from the foregut endoderm, interacts with HNF-
4alpha and suppresses CYP7A1 gene transcription [110]. These authors 
have generated evidence suggesting that Prox1 competes with PGC-
1alpha for HNF-4alpha binding and thus inhibits PGC-1alpha co-
activating activity. The identification of ligands cooperating with HNF-
4alpha and COUP-TFII in the regulation of PED/PEA-15 gene is 
currently in progress in the laboratory and expected to help clarifying the 
mechanism linking PED/PEA-15 overexpression and the genes 
controlling its expression. Indeed, PED/PEA-15 overexpression likely 
represents a molecular abnormality downstream distinct diabetes risk 
genes and serves as an effector of these genes.  
In conclusion, in this first part of my work, I have cloned and 
characterized the PED/PEA-15 promoter, and I have further shown that 
two transcription factors, HNF-4alpha and COUP-TFII, compete for 
binding to the HRE site on PED/PEA-15 gene promoter. While COUP-
TFII increases PED/PEA-15 gene expression, HNF-4alpha antagonizes 
PED/PEA-15 transactivation.  
 
In the previous section of my work, I have clearly established the 
importance of the orphan nuclear receptor HNF-4alpha in the regulation 
of the PED/PEA-15 gene expression. In particular, I have shown that 
HNF-4alpha inhibits PED/PEA-15 gene expression by binding its 
response element (HRE) on the promoter of the gene and by competing 
for the binding with the transcriptional activator COUP-TFII. 
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In this section, I demonstrate that HNF-4alpha inhibits PED/PEA-15 
expression by inducing an eterochromatinization of the core-promoter of 
the gene. In particular, it mediates the assembly of nucleosomes (Fig. 15) 
and leads to an enrichment in markers typical of silent chromatin on 
PED/PEA-15 promoter, such as deacetylated lysines 9 and 14 on histone 
H3 and subsequent di-methylated lysine 9 with a parallel decrease in di-
methylated lysine 4 (Fig. 16). 
Nucleosome, which consists of 146 bp of DNA wrapped around an 
octamer of core histone proteins (H2A, H2B, H3 and H4), is the 
fundamental repeating unit of chromatin. Linker histones of the H1 class 
associate with DNA between single nucleosomes establishing a higher 
level of organization, the so-called “solenoid” helical fibers (30 nm 
fibers). Core histone proteins are evolutionarily conserved and consist 
mainly of flexible amino-terminal tails protruding outward from the 
nucleosome, and globular carboxy-terminal domains making up the 
nucleosome scaffold. Histones function as acceptors for a variety of post-
translational modifications, including acetylation, methylation and 
ubiquitination of lysine (K) residues, phosphorylation of serine (S) and 
threonine (T) residues, and methylation of arginine (R) residues [66; 111-
114]. 
One major challenge in chromatin biology is connecting particular 
modifications with distinct biological functions and vice versa. One of the 
better-understood histone modifications in that aspect is histone 
acetylation. It is now generally accepted that hyperacetylated histones are 
mostly associated with activated genomic regions, at both local and 
global levels. By contrast, deacetylation (leading to hypoacetylation) 
mainly results in repression and silencing [74; 115-118].  
Interestingly, histone methylation appears to have multiple effects on 
chromatin function in a system and site-specific manner. Methylation of 
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H3 on K9, for example, is largely associated with silencing and 
repression in many species. Methylation of H3 on K4, on the other hand, 
is often associated with active or permissive chromatin regions. 
I further demonstrates that HNF-4alpha expression in Hela cells (which 
endogenously express low HNF-4alpha levels) leads to a decrease in 
histone H3 acetylation in the promoter of the PED/PEA-15 gene and, 
conversely, HNF-4alpha silencing in HepG2 cells (which endogenously 
express high HNF-4alpha levels) leads to an increase in this marker 
typical of active promoters (Fig. 16). However, trichostatin A treatment 
of HepG2 cells completely reverts HNF-4alpha action on PED/PEA-15 
gene expression and histone modifications at PED/PEA-15 promoter 
(Fig. 17). 
Thus, it appears that HNF-4alpha provides a scaffold for the assembly of 
histone deacetylating enzymes, thereby providing a mechanistic link 
between the silencing of PED/PEA-15 expression in HepG2 cells and the 
binding of HNF-4alpha to its promoter. 
Repression of gene expression by nuclear receptors is mediated by 
limiting cellular proteins that are recruited to the C-terminal ligand 
binding domain (LBD) of the receptor [119]. These proteins, termed 
corepressors, must fulfill four important criteria, namely: (1) interaction 
with the unliganded receptor; (2) dissociation upon receptor binding of 
activating ligand; (3) potentiation of receptor repression; and (4) intrinsic 
ability to repress transcription of genes to which they are recruited. 
SMRT and N-CoR are related corepressors that influence the 
transcriptional activity of many members of the nuclear receptor 
superfamily. Current working models suggest that in the presence of an 
hormone free nuclear receptor, SMRT and N-CoR and their associated 
inhibitory molecules are recruited to the receptor and block its activation 
of receptor-dependent gene expression. 
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These large molecules can be divided into a C-terminal region that 
interacts with nuclear receptors and an N-terminal region that transmits 
the repression signal to the basal machinery and to chromatin. 
Here we show that HNF-4alpha recruits SMRT to the promoter of the 
Ped/Pea-15 gene (Fig. 18) leading to a decrease in the acetylation of 
histone H3 mainly on lysines 9 and 14 (Fig. 19). Conversely, the 
depletion of SMRT with a specific siRNA completely prevents the 
inhibitory effects of HNF-4alpha on Ped/Pea-15 expression and reverts 
the HNF-4alpha-induced chromatin modifications (Fig. 20). 
An ever growing number of modification sites on both histone-tail and 
non-tail domains have been identified [66]. For example, lysine residues 
in histones can be modified by acetylation, mono-ubiquitination or mono-
, di-, and tri-methylation. [66; 120]. Although it remains unclear as to 
what extent, if at all, individual residues undergo “choices” of 
modification, it is well documented that H3-K9 and H3-K14 can be either 
acetylated or (mono, di-, tri-) methylated [121; 122]. Obvioulsy different 
marks on the same site cannot co-exist, and therefore, they exclude each 
other. An acetyl group, for example, must be removed before a methyl 
group can be added and complexes that contain both histone deacetylases 
(HDACs) and HMTs have now been identified [123-125]. So far, the 
amino-terminal tail of histone H3 has the highest density of post-
translational modifications mapped among all histones, and a complex 
pattern of putative combinations of marks is emerging. Methylation of 
H3-K9, for example, appears to trigger sequencial events leading 
ultimately to transcriptional repression [126]. At least in vitro, this mark 
can inhibit acetylation of the H3 tail (on K14, K18 and K23) by histone 
acetyltransferase (HAT) such as p300 [126], and methylation of H3-K4 
by HMTs such as Set7 [126]. By contrast, H3-K4 methylation inhibits K9 
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methylation by Su(var)3-9, but promotes acetylation of H3 by p300 
[126]. 
Finally my results indicate that HNF-4alpha induces the packaging of the 
PED/PEA-15 promoter acting as a scaffold for a “bridge-like” structure 
where SMRT, recruited by HNF-4alpha to PED/PEA-15 promoter, 
deacetylates histone H3, leads to the inhibitory di-methylation of H3-K9 
and this results in the silencing of PED/PEA-15 expression. 
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